十米阳光 personal page - To The Moon

十米阳光

十米阳光

No personal profile

36Follow

7Followers

0Topic

0Badge

2021-09-17

$Upstart Holdings, Inc.(UPST)$crazy!

2021-08-24

nonsense.

Sorry, the original content has been removed

2021-08-24

bullshit.

Sorry, the original content has been removed

2021-07-23

They don't have any item in production yet.

Here's Why Cassava Sciences Is Surging Today

2021-03-28

She has too many positions, that's why She dare not to be bearish.

Here's why Cathie Wood and Kevin O'Leary are still bullish on growth stocks

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3475060425489605,"uuid":"3475060425489605","gmtCreate":1511966405090,"gmtModify":1616983469266,"name":"十米阳光","pinyin":"smygshimiyangguang","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":36,"tweetSize":46,"questionSize":0,"limitLevel":900,"accountStatus":3,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":53,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":884847930,"gmtCreate":1631883501820,"gmtModify":1676530660803,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/UPST\">$Upstart Holdings, Inc.(UPST)$</a>crazy!","listText":"<a href=\"https://laohu8.com/S/UPST\">$Upstart Holdings, Inc.(UPST)$</a>crazy!","text":"$Upstart Holdings, Inc.(UPST)$crazy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884847930","isVote":1,"tweetType":1,"viewCount":258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834542897,"gmtCreate":1629815668819,"gmtModify":1676530140914,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"nonsense.","listText":"nonsense.","text":"nonsense.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834542897","repostId":"2161700531","repostType":2,"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834543225,"gmtCreate":1629815516567,"gmtModify":1676530140762,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"bullshit.","listText":"bullshit.","text":"bullshit.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834543225","repostId":"2161700531","repostType":2,"isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175089939,"gmtCreate":1626998487021,"gmtModify":1703482031415,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"They don't have any item in production yet.","listText":"They don't have any item in production yet.","text":"They don't have any item in production yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175089939","repostId":"1146624774","repostType":2,"repost":{"id":"1146624774","pubTimestamp":1626926115,"share":"https://www.laohu8.com/m/news/1146624774?lang=&edition=full","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li>\n</ul>\n<h2><b>What happened</b></h2>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p>\n<h2><b>So what</b></h2>\n<p>The FDA's controversial approval of Aduhelm from&nbsp;<b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b>&nbsp;this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p>\n<p><img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p>\n<h2><b>Now what</b></h2>\n<p>Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p>\n<p>Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1},"isVote":1,"tweetType":1,"viewCount":591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":352864115,"gmtCreate":1616930989637,"gmtModify":1704800040723,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"She has too many positions, that's why She dare not to be bearish.","listText":"She has too many positions, that's why She dare not to be bearish.","text":"She has too many positions, that's why She dare not to be bearish.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/352864115","repostId":"1192588043","repostType":4,"repost":{"id":"1192588043","pubTimestamp":1616765117,"share":"https://www.laohu8.com/m/news/1192588043?lang=&edition=full","pubTime":"2021-03-26 21:25","market":"fut","language":"en","title":"Here's why Cathie Wood and Kevin O'Leary are still bullish on growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1192588043","media":"CNN Business","summary":"New York (CNN Business) - Tech stocks have taken a hit lately as investors continue to seek comfort ","content":"<p><b>New York (CNN Business)&nbsp;-&nbsp;</b>Tech stocks have&nbsp;taken a hit lately&nbsp;as investors continue to seek comfort in banks, big oil and other value sectors. But some fans of trendy momentum stocks aren't giving up on them just yet.</p>\n<p>That's the message from Cathie Wood of Ark Invest — who has become one of the&nbsp;more influential voices on Wall Street&nbsp;and is a major backer of&nbsp;Tesla&nbsp;(TSLA)— and two other titans of growth investing, who shared their investment insights Thursday.</p>\n<p>\"We've seen higher valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said during a webcast hosted by&nbsp;Cboe&nbsp;(CBOE)&nbsp;Global Markets.</p>\n<p>Wood joined Kevin O'Leary of \"Shark Tank\" fame (he also runs a family of&nbsp;O'Shares ETFs) and Jan van Eck, whose firm recently launched the&nbsp;BUZZ ETF&nbsp;that tracks&nbsp;stocks popular on social media, for the Cboe chat.</p>\n<p>Wood noted that investors are shifting their money into more so-called cyclical areas — those dependent on the success of the economy, like retailers and airlines — and said that's a good thing. She's encouraged to see that the broader market rally is broadening even further.</p>\n<p><b>The bullish case for growth stocks still exists</b></p>\n<p>As the economy continues its fragile recovery, fears about bond yields and inflation have been high. But all three of the fund managers said they are not too worried about these trends hurting growth stocks.</p>\n<p>They also stressed that younger individual investors will continue to play a big role in the market thanks to the rise of zero commission brokerage firms: \"There are a lot of retail investors playing in the market thanks to Robinhood and Coinbase. Individual investors are more engaged,\" van Eck said.</p>\n<p>He says investors should flock more to companies that have a big competitive advantage, such as those in his firm'sWide Moat ETF(MOAT)— which invests in stocks that are dominant in their respective fields, like its key holdings including&nbsp;Charles Schwab&nbsp;(SCHW),Intel&nbsp;(INTC),Microsoft&nbsp;(MSFT)&nbsp;and&nbsp;Amazon(AMZN).</p>\n<p>O'Leary, too, believes the stock market boom can last, saying he $1.9 trillion in new stimulus is \"free money\" for many investors. But he's not buying into the notion that cyclical stocks can continue to outperform tech for much longer.</p>\n<p>\"Yes, people are seeking quality. But some sectors are permanently damaged and airlines are one of them due to technology,\" he said. \"I don't need to fly to Dubai as much anymore for meetings when were doing Zoom calls every week.\"</p>\n<p>O'Leary said he is also willing to make some speculative bets on emerging industries that aren't getting a lot of attention. For example, O'Leary's firm owns shares of&nbsp;MindMed&nbsp;(MMEDF), which is working on developing legal psychedelic medications that can be used to help treat depression, anxiety and other mental health disorders.</p>\n<p>Wood is also investing in innovative health care companies, with oneArk ETF devoted to genomics&nbsp;(ARKG). And she thinks younger investors, many of whom are inheriting money from baby boomers, will continue to gravitate toward more dynamic fields like robotics and alternative energy. So she's not too concerned that the recent rebound in value stocks spells an end to the tech renaissance.</p>\n<p>\"A lot of companies catering to short-term investors who wanted profits now invested more in stock buybacks and dividends over innovation,\" Wood said. \"That puts them in harm's way.\"</p>\n<p><b>'Prime time' for bitcoin coming?</b></p>\n<p>Wood also thinks bitcoin is ready for \"prime time\" and that prices will continue climbing over the long haul as more companies will adopt crypto-friendly strategies like Tesla andSquar(SQ)have done. In fact, Wood said she thinks it makes sense for investors to have between 2.5% and 6.5% of their assets in bitcoin, adding that her funds are betting on crypto primarily through the publicly traded Grayscale Bitcoin Trus.(GBTC)</p>\n<p>O'Leary, meanwhile, had been somewhat skeptical of bitcoin a few years ago. But he said Thursday that he is growing more convinced that bitcoin will gain traction, and he believes it makes to have about 3% of a portfolio in bitcoin as well as crypto miner stocks.</p>\n<p>And van Eck noted that the upcoming&nbsp;market debut of Coinbase&nbsp;will be one to watch — at a potential valuation of $100 billion following its direct listing, the stock would dwarf the roughly $24 billion market value of&nbsp;Nasda.(NDAQ)</p>\n<p>With that in mind, van Eck expects more big investment firms to try to cash in on bitcoin or risk being left out.Fidelit,(EFIPX)&nbsp;for example, just jointed a growing list of firms filing to launch a crypto ETF with the SEC.</p>\n<p>\"Crypto Wall Street will be a disruptive threat to traditional banks and institutions,\" van Eck said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's why Cathie Wood and Kevin O'Leary are still bullish on growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's why Cathie Wood and Kevin O'Leary are still bullish on growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-26 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/03/25/investing/cathie-wood-kevin-oleary-vaneck-stocks/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business) - Tech stocks have taken a hit lately as investors continue to seek comfort in banks, big oil and other value sectors. But some fans of trendy momentum stocks aren't giving up ...</p>\n\n<a href=\"https://edition.cnn.com/2021/03/25/investing/cathie-wood-kevin-oleary-vaneck-stocks/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","ARKG":"ARK Genomic Revolution ETF","GBTC":"Grayscale Bitcoin Trust",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://edition.cnn.com/2021/03/25/investing/cathie-wood-kevin-oleary-vaneck-stocks/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192588043","content_text":"New York (CNN Business) - Tech stocks have taken a hit lately as investors continue to seek comfort in banks, big oil and other value sectors. But some fans of trendy momentum stocks aren't giving up on them just yet.\nThat's the message from Cathie Wood of Ark Invest — who has become one of the more influential voices on Wall Street and is a major backer of Tesla (TSLA)— and two other titans of growth investing, who shared their investment insights Thursday.\n\"We've seen higher valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said during a webcast hosted by Cboe (CBOE) Global Markets.\nWood joined Kevin O'Leary of \"Shark Tank\" fame (he also runs a family of O'Shares ETFs) and Jan van Eck, whose firm recently launched the BUZZ ETF that tracks stocks popular on social media, for the Cboe chat.\nWood noted that investors are shifting their money into more so-called cyclical areas — those dependent on the success of the economy, like retailers and airlines — and said that's a good thing. She's encouraged to see that the broader market rally is broadening even further.\nThe bullish case for growth stocks still exists\nAs the economy continues its fragile recovery, fears about bond yields and inflation have been high. But all three of the fund managers said they are not too worried about these trends hurting growth stocks.\nThey also stressed that younger individual investors will continue to play a big role in the market thanks to the rise of zero commission brokerage firms: \"There are a lot of retail investors playing in the market thanks to Robinhood and Coinbase. Individual investors are more engaged,\" van Eck said.\nHe says investors should flock more to companies that have a big competitive advantage, such as those in his firm'sWide Moat ETF(MOAT)— which invests in stocks that are dominant in their respective fields, like its key holdings including Charles Schwab (SCHW),Intel (INTC),Microsoft (MSFT) and Amazon(AMZN).\nO'Leary, too, believes the stock market boom can last, saying he $1.9 trillion in new stimulus is \"free money\" for many investors. But he's not buying into the notion that cyclical stocks can continue to outperform tech for much longer.\n\"Yes, people are seeking quality. But some sectors are permanently damaged and airlines are one of them due to technology,\" he said. \"I don't need to fly to Dubai as much anymore for meetings when were doing Zoom calls every week.\"\nO'Leary said he is also willing to make some speculative bets on emerging industries that aren't getting a lot of attention. For example, O'Leary's firm owns shares of MindMed (MMEDF), which is working on developing legal psychedelic medications that can be used to help treat depression, anxiety and other mental health disorders.\nWood is also investing in innovative health care companies, with oneArk ETF devoted to genomics (ARKG). And she thinks younger investors, many of whom are inheriting money from baby boomers, will continue to gravitate toward more dynamic fields like robotics and alternative energy. So she's not too concerned that the recent rebound in value stocks spells an end to the tech renaissance.\n\"A lot of companies catering to short-term investors who wanted profits now invested more in stock buybacks and dividends over innovation,\" Wood said. \"That puts them in harm's way.\"\n'Prime time' for bitcoin coming?\nWood also thinks bitcoin is ready for \"prime time\" and that prices will continue climbing over the long haul as more companies will adopt crypto-friendly strategies like Tesla andSquar(SQ)have done. In fact, Wood said she thinks it makes sense for investors to have between 2.5% and 6.5% of their assets in bitcoin, adding that her funds are betting on crypto primarily through the publicly traded Grayscale Bitcoin Trus.(GBTC)\nO'Leary, meanwhile, had been somewhat skeptical of bitcoin a few years ago. But he said Thursday that he is growing more convinced that bitcoin will gain traction, and he believes it makes to have about 3% of a portfolio in bitcoin as well as crypto miner stocks.\nAnd van Eck noted that the upcoming market debut of Coinbase will be one to watch — at a potential valuation of $100 billion following its direct listing, the stock would dwarf the roughly $24 billion market value of Nasda.(NDAQ)\nWith that in mind, van Eck expects more big investment firms to try to cash in on bitcoin or risk being left out.Fidelit,(EFIPX) for example, just jointed a growing list of firms filing to launch a crypto ETF with the SEC.\n\"Crypto Wall Street will be a disruptive threat to traditional banks and institutions,\" van Eck said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":352864115,"gmtCreate":1616930989637,"gmtModify":1704800040723,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"She has too many positions, that's why She dare not to be bearish.","listText":"She has too many positions, that's why She dare not to be bearish.","text":"She has too many positions, that's why She dare not to be bearish.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/352864115","repostId":"1192588043","repostType":4,"isVote":1,"tweetType":1,"viewCount":691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884847930,"gmtCreate":1631883501820,"gmtModify":1676530660803,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/UPST\">$Upstart Holdings, Inc.(UPST)$</a>crazy!","listText":"<a href=\"https://laohu8.com/S/UPST\">$Upstart Holdings, Inc.(UPST)$</a>crazy!","text":"$Upstart Holdings, Inc.(UPST)$crazy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884847930","isVote":1,"tweetType":1,"viewCount":258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834542897,"gmtCreate":1629815668819,"gmtModify":1676530140914,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"nonsense.","listText":"nonsense.","text":"nonsense.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834542897","repostId":"2161700531","repostType":2,"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834543225,"gmtCreate":1629815516567,"gmtModify":1676530140762,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"bullshit.","listText":"bullshit.","text":"bullshit.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834543225","repostId":"2161700531","repostType":2,"isVote":1,"tweetType":1,"viewCount":367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175089939,"gmtCreate":1626998487021,"gmtModify":1703482031415,"author":{"id":"3475060425489605","authorId":"3475060425489605","name":"十米阳光","avatar":"https://static.tigerbbs.com/28d860247a59068802092163fb7e35c2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"They don't have any item in production yet.","listText":"They don't have any item in production yet.","text":"They don't have any item in production yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175089939","repostId":"1146624774","repostType":2,"isVote":1,"tweetType":1,"viewCount":591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}